ABSTRACT
Negative allosteric modulators (NAMs) of metabotropic glutamate receptor 5 (mGlu5) have potential for the treatment of psychiatric diseases including depression, fragile X syndrome (FXS), anxiety, obsessive-compulsive disorders, and levodopa induced dyskinesia in Parkinson's disease. Herein we report the optimization of a weakly active screening hit 1 to the potent and selective compounds chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, 2) and 2-chloro-4-((2,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1H-imidazol-4-yl)ethynyl)pyridine (CTEP, 3). Compound 2 is active in a broad range of anxiety tests reaching the same efficacy but at a 10- to 100-fold lower dose compared to diazepam and is characterized by favorable DMPK properties in rat and monkey as well as an excellent preclinical safety profile and is currently in phase II clinical studies for the treatment of depression and fragile X syndrome. Analogue 3 is the first reported mGlu5 NAM with a long half-life in rodents and is therefore an ideal tool compound for chronic studies in mice and rats.
Subject(s)
Depression/drug therapy , Drug Discovery , Fragile X Syndrome/drug therapy , Imidazoles/pharmacology , Pyridines/pharmacology , Receptor, Metabotropic Glutamate 5/antagonists & inhibitors , Allosteric Regulation/drug effects , Animals , Dose-Response Relationship, Drug , Humans , Imidazoles/chemical synthesis , Imidazoles/chemistry , Macaca mulatta , Male , Mice , Mice, Inbred Strains , Molecular Structure , Pyridines/chemical synthesis , Pyridines/chemistry , Rats , Rats, Sprague-Dawley , Rats, Wistar , Structure-Activity RelationshipABSTRACT
The metabotropic glutamate receptor 5 (mGlu5) is a glutamate-activated class C G protein-coupled receptor widely expressed in the central nervous system and clinically investigated as a drug target for a range of indications, including depression, Parkinson's disease, and fragile X syndrome. Here, we present the novel potent, selective, and orally bioavailable mGlu5 negative allosteric modulator with inverse agonist properties 2-chloro-4-((2,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1H-imidazol-4-yl)ethynyl)pyridine (CTEP). CTEP binds mGlu5 with low nanomolar affinity and shows >1000-fold selectivity when tested against 103 targets, including all known mGlu receptors. CTEP penetrates the brain with a brain/plasma ratio of 2.6 and displaces the tracer [(3)H]3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone-O-methyl-oxime (ABP688) in vivo in mice from brain regions expressing mGlu5 with an average ED(50) equivalent to a drug concentration of 77.5 ng/g in brain tissue. This novel mGlu5 inhibitor is active in the stress-induced hyperthermia procedure in mice and the Vogel conflict drinking test in rats with minimal effective doses of 0.1 and 0.3 mg/kg, respectively, reflecting a 30- to 100-fold higher in vivo potency compared with 2-methyl-6-(phenylethynyl)pyridine (MPEP) and fenobam. CTEP is the first reported mGlu5 inhibitor with both long half-life of approximately 18 h and high oral bioavailability allowing chronic treatment with continuous receptor blockade with one dose every 48 h in adult and newborn animals. By enabling long-term treatment through a wide age range, CTEP allows the exploration of the full therapeutic potential of mGlu5 inhibitors for indications requiring chronic receptor inhibition.
Subject(s)
Behavior, Animal/drug effects , Brain/metabolism , Fever/drug therapy , Imidazoles/pharmacology , Imidazoles/pharmacokinetics , Pyridines/pharmacology , Pyridines/pharmacokinetics , Receptors, Metabotropic Glutamate/antagonists & inhibitors , Administration, Oral , Allosteric Regulation/drug effects , Animals , Anti-Anxiety Agents/pharmacology , Biological Availability , Blood-Brain Barrier/drug effects , Brain/drug effects , Calcium/metabolism , Cyclic AMP/metabolism , Drug Evaluation, Preclinical , HEK293 Cells , Humans , Imidazoles/administration & dosage , Imidazoles/metabolism , Inositol Phosphates/metabolism , Male , Mice , Molecular Targeted Therapy , Plasmids , Pyridines/administration & dosage , Pyridines/metabolism , Radioligand Assay , Rats , Rats, Sprague-Dawley , Receptor, Metabotropic Glutamate 5 , Receptors, Metabotropic Glutamate/agonistsABSTRACT
Through iterative design cycles we have discovered a number of novel new classes where the imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepine was deemed the most promising GABA(A) alpha5 inverse agonist class with potential for cognitive enhancement. This class combines a modest subtype binding selectivity with inverse agonism and has the most favourable molecular properties for further lead optimisation towards a central nervous system (CNS) acting medicine.
Subject(s)
Benzodiazepines/chemistry , Nootropic Agents/chemistry , Receptors, GABA-A/metabolism , Triazoles/chemistry , Animals , Benzodiazepines/chemical synthesis , Benzodiazepines/pharmacology , Drug Discovery , Drug Inverse Agonism , GABA-A Receptor Agonists , Humans , Nootropic Agents/chemical synthesis , Nootropic Agents/pharmacology , Oocytes/drug effects , Triazoles/chemical synthesis , Triazoles/pharmacology , Xenopus laevisABSTRACT
Optimization of affinity and microsomal stability led to identification of the potent, metabolically stable fenobam analog 4l. Robust in vivo efficacy of 4l was demonstrated in four different models of anxiety. Additionally, a ligand based pharmacophore alignment of fenobam and MPEP is proposed.
Subject(s)
Imidazoles/chemistry , Imidazoles/pharmacology , Receptors, Metabotropic Glutamate/antagonists & inhibitors , Animals , Anti-Anxiety Agents/chemical synthesis , Drug Design , Humans , Ligands , Pyridines/chemistry , Receptor, Metabotropic Glutamate 5 , Structure-Activity RelationshipABSTRACT
Optimisation of affinity, chemical stability, metabolic stability and solubility led from a chemically labile HTS hit 1 to mGlu5 receptor antagonists (24-26) with high affinity for the allosteric MPEP binding site, improved microsomal metabolic stability and anxiolytic-like activity in vivo as assessed by the Vogel conflict drinking test.
Subject(s)
Excitatory Amino Acid Antagonists/pharmacology , Pyridines/pharmacology , Receptors, Metabotropic Glutamate/antagonists & inhibitors , Administration, Oral , Excitatory Amino Acid Antagonists/administration & dosage , Excitatory Amino Acid Antagonists/chemistry , Pyridines/administration & dosage , Pyridines/chemistryABSTRACT
Fenobam [N-(3-chlorophenyl)-N'-(4,5-dihydro-1-methyl-4-oxo-1H-imidazole-2-yl)urea] is an atypical anxiolytic agent with unknown molecular target that has previously been demonstrated both in rodents and human to exert anxiolytic activity. Here, we report that fenobam is a selective and potent metabotropic glutamate (mGlu)5 receptor antagonist acting at an allosteric modulatory site shared with 2-methyl-6-phenylethynyl-pyridine (MPEP), the protypical selective mGlu5 receptor antagonist. Fenobam inhibited quisqualate-evoked intracellular calcium response mediated by human mGlu5 receptor with IC(50) = 58 +/- 2 nM. It acted in a noncompetitive manner, similar to MPEP and demonstrated inverse agonist properties, blocking 66% of the mGlu5 receptor basal activity (in an over expressed cell line) with an IC(50) = 84 +/- 13 nM. [(3)H]Fenobam bound to rat and human recombinant receptors with K(d) values of 54 +/- 6 and 31 +/- 4 nM, respectively. MPEP inhibited [(3)H]fenobam binding to human mGlu5 receptors with a K(i) value of 6.7 +/- 0.7 nM, indicating a common binding site shared by both allosteric antagonists. Fenobam exhibits anxiolytic activity in the stress-induced hyperthermia model, Vogel conflict test, Geller-Seifter conflict test, and conditioned emotional response with a minimum effective dose of 10 to 30 mg/kg p.o. Furthermore, fenobam is devoid of GABAergic activity, confirming previous reports that fenobam acts by a mechanism distinct from benzodiazepines. The non-GABAergic activity of fenobam, coupled with its robust anxiolytic activity and reported efficacy in human in a double blind placebo-controlled trial, supports the potential of developing mGlu5 receptor antagonists with an improved therapeutic window over benzodiazepines as novel anxiolytic agents.
Subject(s)
Anti-Anxiety Agents/pharmacology , Imidazoles/pharmacology , Pyridines/pharmacology , Receptors, Metabotropic Glutamate/agonists , Receptors, Metabotropic Glutamate/antagonists & inhibitors , Animals , CHO Cells , Cell Line , Cells, Cultured , Conditioning, Operant/drug effects , Conflict, Psychological , Cricetinae , Cyclic AMP/metabolism , DNA, Complementary/biosynthesis , DNA, Complementary/genetics , Drinking Behavior/drug effects , Emotions/drug effects , Fever/physiopathology , Guanosine 5'-O-(3-Thiotriphosphate)/metabolism , Humans , Inositol Phosphates/metabolism , Male , Mice , Plasmids/genetics , Rats , Rats, Sprague-Dawley , Receptor, Metabotropic Glutamate 5 , Stress, Physiological/physiopathologyABSTRACT
Screening of the Roche compound depository led to the identification of (1-benzyloxy-4,5-dihydro-1H-imidazol-2-yl)-butyl amine 4, a structurally novel NR1/2B subtype selective NMDA receptor antagonist. The structure-activity relationships developed in this series resulted in the discovery of a novel class of potent and selective NMDA receptor blockers displaying activity in vivo.
Subject(s)
Excitatory Amino Acid Antagonists/chemistry , Imidazoles/chemistry , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Animals , Cells, Cultured , Excitatory Amino Acid Antagonists/administration & dosage , Excitatory Amino Acid Antagonists/pharmacology , Imidazoles/administration & dosage , Imidazoles/pharmacology , Injections, Intraperitoneal , Mice , Mice, Inbred DBA , Potassium Channels, Voltage-Gated/antagonists & inhibitors , Receptors, N-Methyl-D-Aspartate/physiology , Seizures/prevention & controlABSTRACT
A series of 4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and analogous quinolines was prepared and evaluated as NR1/2B subtype selective NMDA receptor antagonists. 2-Hydroxyalkylamino substitution combines high affinity with selectivity (vs alpha1 and M1 receptors) and activity in vivo.
Subject(s)
Pyridines/chemical synthesis , Quinolines/chemical synthesis , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Animals , Mice , Pyridines/pharmacology , Quinolines/pharmacology , Seizures/drug therapy , Structure-Activity RelationshipABSTRACT
Recently, we disclosed 4-aminoquinolines as structurally novel NR1/2B subtype selective NMDA receptor antagonists. We would now like to report our findings on structurally related pyridine analogues. The SAR developed in this series resulted in the discovery of high affinity antagonists which are selective (vs alpha1 and M1 receptors) and active in vivo.
Subject(s)
Isoquinolines/chemistry , Isoquinolines/pharmacology , Pyridines/chemistry , Pyridines/pharmacology , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Acoustic Stimulation , Animals , Dose-Response Relationship, Drug , Excitatory Amino Acid Antagonists/chemistry , Excitatory Amino Acid Antagonists/pharmacology , Hydrogen-Ion Concentration , Mice , Mice, Inbred DBA , Seizures/etiology , Seizures/prevention & control , Structure-Activity RelationshipABSTRACT
Screening of the Roche compound library led to the identification of 4-aminoquinoline 4 as structurally novel NR1/2B subtype selective NMDA receptor antagonist. The SAR which was developed in this series resulted in the discovery of highly potent and in vivo active blockers.